---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093947"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:28:10.710147+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q2 net loss $5.8M as revenue falls 56% to $1.4M

## Summary
- Net loss attributable to Lineage $5.8M ($0.03/share) vs $5.2M prior year; revenue $1.4M vs $3.2M.
- Cash and equivalents $38.5M as of June 30; expected to fund operations into Q4 2025.
- OpRegen Phase 1/2a data: mean BCVA gain +5.5 letters at 24 months in less advanced GA patients (n=10).
- OPC1 spinal cord injury study startup activities ongoing; hosted 2nd Annual SCI Investor Symposium.
- Services agreement with Genentech initiated for OpRegen development support, fully funded by Genentech.

## SEC filing metadata
- accession: 0000950170-24-093947
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024093947/0000950170-24-093947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024093947/lctx-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093947
- JSON: https://secwatch.observer/filing/0000950170-24-093947.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.